Literature DB >> 2580177

Blood pressure and metabolic responses to hydrochlorothiazide, captopril, and the combination in black and white mild-to-moderate hypertensive patients.

M H Weinberger.   

Abstract

Mild-to-moderate essential hypertensive patients (255) were assigned to receive hydrochlorothiazide 15 mg three times a day, captopril 25 mg three times a day, or both. A significant decline in blood pressure was seen in 84% of patients taking both agents, while 43% of those taking captopril and 64% of those taking hydrochlorothiazide showed a significant blood pressure response. Among white hypertensives receiving captopril alone, a normalization of blood pressure occurred in 46% and a significant reduction in 8% was observed which was significantly (p less than 0.05) higher than that observed in black subjects where only 31% showed a normalization of their pressure with captopril alone. With hydrochlorothiazide, 53% of blacks and 54% of whites showed normalization of their pressures. With the combination, over 80% of the patients in both racial groups demonstrated a normalization or significant reduction in blood pressure. With hydrochlorothiazide alone, significant (p less than 0.05) decreases in serum potassium, increases in uric acid, blood glucose, and blood cholesterol were seen. With captopril alone, no changes in any of these measurements were observed. When captopril was added to hydrochlorothiazide, a significant attenuation of the diuretic effect on potassium and uric acid was observed, and the significant change in blood sugar and cholesterol seen with the diuretic alone was prevented. These observations suggest that there are heterogeneous responses to hypertensive monotherapy based on race. Furthermore, it suggests that when a single therapeutic agent is not adequate in controlling blood pressure to the desired levels, the addition of either hydrochlorothiazide or captopril should produce a further reduction in blood pressure.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2580177     DOI: 10.1097/00005344-198507001-00011

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  35 in total

Review 1.  Monotherapy versus combination therapy as first line treatment of uncomplicated arterial hypertension.

Authors:  M Ruzicka; F H Leenen
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 2.  ACE inhibitors in the prevention and therapy of diabetic nephropathy. What is their role?

Authors:  C C Kelleher
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

3.  Angiotensin-converting enzyme inhibitors or calcium channel blockers? An overview.

Authors:  H Gavras
Journal:  Drugs       Date:  1990       Impact factor: 9.546

Review 4.  Recent Advances in Pharmacological Management of Hypertension in Diabetic Patients with Nephropathy : Effects of Antihypertensive Drugs on Kidney Function and Insulin Sensitivity.

Authors:  Tsuneharu Baba; Takashi Ishizaki
Journal:  Drugs       Date:  1992-04       Impact factor: 9.546

Review 5.  Angiotensin converting enzyme inhibitors and moderate hypertension.

Authors:  D McAreavey; J I Robertson
Journal:  Drugs       Date:  1990-09       Impact factor: 9.546

Review 6.  Captopril and hydrochlorothiazide: rationale for their combination.

Authors:  E Ambrosioni; C Borghi; F V Costa
Journal:  Br J Clin Pharmacol       Date:  1987       Impact factor: 4.335

7.  Determination of the optimal dosage regimen of captopril + hydrochlorothiazide in the treatment of moderate arterial hypertension.

Authors:  D Steru; M Childs; S Lancrenon; J M Languillat; A Mattei; B Millet; A Schwebig; A Stephan
Journal:  Br J Clin Pharmacol       Date:  1987       Impact factor: 4.335

Review 8.  Fixed-dose combinations as initial therapy for hypertension: a review of approved agents and a guide to patient selection.

Authors:  Bernard Waeber; François Feihl; Luis M Ruilope
Journal:  Drugs       Date:  2009       Impact factor: 9.546

9.  A double-blind comparison of the effects of carvedilol and captopril on serum lipid concentrations in patients with mild to moderate essential hypertension and dyslipidaemia.

Authors:  U Hauf-Zachariou; L Widmann; B Zülsdorf; M Hennig; P D Lang
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 10.  Pharmacokinetic drug interactions with ACE inhibitors.

Authors:  H Shionoiri
Journal:  Clin Pharmacokinet       Date:  1993-07       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.